Ipilimumab and BRAF inhibitors for advanced melanoma

PDL1 inhibitors in melanoma

Comment on drug developments in advanced melanoma

Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma

Classification and immunohistochemical approach of intracranial germ cell tumours

Biomarker analyses in emerging data from PI3K/AKT/mTOR programme clinical trials

Integrating breast cancer genomics and proteomics

Next wave of successful drug therapy strategies in HER2-positive breast cancer

CD4 T cells in extensively inflitrated breast cancer signal organised immune response and predict survival

How do we design trials that improve outcome?

The future of PI3K/AKT/mTOR inhibitors in breast cancer

Update on the METABRIC consortium 2000 Breast Cancer Study